Upregulation of IGF2R evades lysosomal dysfunction-induced apoptosis of cervical cancer cells via transport of cathepsins (本文)

1. Bray, F. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 68, 394–424 (2018).

2. Bruni, L. et al. Global estimates of human papillomavirus vaccination coverage by region and income level: a pooled analysis. Lancet Glob. Health 4, e453–e463 (2016).

3. Cohen, P. A., Jhingran, A., Oaknin, A. & Denny, L. Cervical cancer. Lancet (London, England) 393, 169–182 (2019).

4. Lobel, P., Dahms, N. M. & Kornfeld, S. Cloning and sequence analysis of the cation-independent mannose 6-phosphate receptor. J. Biol. Chem. 263, 2563–2570 (1988).

5. Oshima, A., Nolan, C. M., Kyle, J. W., Grubb, J. H. & Sly, W. S. The human cation- independent mannose 6-phosphate receptor. Cloning and sequence of the full-length cDNA and expression of functional receptor in COS cells. J. Biol. Chem. 263, 2553–2562 (1988).

6. Brown, J. et al. Structure of a functional IGF2R fragment determined from the anomalous scattering of sulfur. EMBO J. 21, 1054–1062 (2002).

7. Harris, L. K. & Westwood, M. Biology and significance of signalling pathways activated by IGF-II. Growth Factors 30, 1–12 (2012).

8. Martin-Kleiner, I. & Gall Troselj, K. Mannose-6-phosphate/insulin-like growth factor 2 receptor (M6P/IGF2R) in carcinogenesis. Cancer Lett. 289, 11–22 (2010).

9. Sheng, Z. M. et al. Multiple regions of chromosome 6q affected by loss of heterozygosity in primary human breast carcinomas. Br. J. Cancer 73, 144–147 (1996).

10. De Souza, A. T., Hankins, G. R., Washington, M. K., Orton, T. C.& Jirtle, R. L. M6P/ IGF2R gene is mutated in human hepatocellular carcinomas with loss of heterozygosity. Nat. Genet. 11, 447–449 (1995).

11. Saito, S. et al. Definition of a commonly deleted region in ovarian cancers to a 300-kb segment of chromosome 6q27. Cancer Res. 56, 5586–5589 (1996).

12. Wise, T. L. & Pravtcheva, D. D. Delayed onset of Igf2-induced mammary tumors in Igf2r transgenic mice. Cancer Res. 66, 1327–1336 (2006).

13. Lee, J. S., Weiss, J., Martin, J. L. & Scott, C. D. Increased expression of the mannose 6-phosphate/insulin-like growth factor-II receptor in breast cancer cells alters tumorigenic properties in vitro and in vivo. Int. J. Cancer 107, 564–570 (2003).

14. O’Gorman, D. B., Weiss, J., Hettiaratchi, A., Firth, S. M. & Scott, C. D. Insulin-like growth factor-II/mannose 6-phosphate receptor overexpression reduces growth of choriocarcinoma cells in vitro and in vivo. Endocrinology 143, 4287–4294 (2002).

15. Chen, Z., Ge, Y., Landman, N. & Kang, J. X. Decreased expression of the mannose 6-phosphate/insulin-like growth factor-II receptor promotes growth of human breast cancer cells. BMC Cancer 2, 18 (2002).

16. Saftig, P. & Klumperman, J. Lysosome biogenesis and lysosomal membrane proteins: trafficking meets function. Nat. Rev. Mol. Cell Biol. 10, 623–635 (2009).

17. Goda, Y. & Pfeffer, S. R. Selective recycling of the mannose 6-phosphate/IGF-II receptor to the trans Golgi network in vitro. Cell 55, 309–320 (1988).

18. Griffiths, G., Hoflack, B., Simons, K., Mellman, I. & Kornfeld, S. The mannose 6- phosphate receptor and the biogenesis of lysosomes. Cell 52, 329–341 (1988).

19. Boya, P. & Kroemer, G. Lysosomal membrane permeabilization in cell death. Oncogene 27, 6434–6451 (2008).

20. Kaur, J. & Debnath, J. Autophagy at the crossroads of catabolism and ana- bolism. Nat. Rev. Mol. Cell Biol. 16, 461–472 (2015).

21. Doray, B., Bruns, K., Ghosh, P. & Kornfeld, S. Interaction of the cation-dependent mannose 6-phosphate receptor with GGA proteins. J. Biol. Chem. 277, 18477–18482 (2002).

22. Ghosh, P. & Kornfeld, S. The cytoplasmic tail of the cation-independent mannose 6-phosphate receptor contains four binding sites for AP-1. Arch. Biochem. Biophys. 426, 225–230 (2004).

23. Scott, G. K., Fei, H., Thomas, L., Medigeshi, G. R.& Thomas, G.A PACS-1, GGA3 and CK2 complex regulates CI-MPR trafficking. EMBO J. 25, 4423–4435 (2006).

24. Stöckli, J., Höning, S. & Rohrer, J. The acidic cluster of the CK2 site of the cation- dependent mannose 6-phosphate receptor (CD-MPR) but not its phosphor- ylation is required for GGA1 and AP-1 binding. J. Biol. Chem. 279, 23542–23549 (2004).

25. Dasari, S., Wudayagiri, R. & Valluru, L. Cervical cancer: Biomarkers for diagnosis and treatment. Clin. Chim. Acta. 445, 7–11 (2015).

26. Network, C. G. A. R. et al. Integrated genomic and molecular characterization of cervical cancer. Nature 543, 378–384 (2017).

27. Hou, M. M. et al. Targeted PI3K/AKT/mTOR therapy for metastatic carcinomas of the cervix: A phase I clinical experience. Oncotarget 5, 11168–11179 (2014).

28. Funk, B. et al. Expression of the insulin-like growth factor-II/mannose-6-phos- phate receptor in multiple human tissues during fetal life and early infancy. J. Clin. Endocrinol. Metab. 75, 424–431 (1992).

29. Lemamy, G. J. et al. High-affinity antibodies from hen’s-egg yolks against human mannose-6-phosphate/insulin-like growth-factor-II receptor (M6P/ IGFII-R): characterization and potential use in clinical cancer studies. Int. J. Cancer 80, 896–902 (1999).

30. Varghese, R. T. et al. Survival kinase genes present prognostic significance in glioblastoma. Oncotarget 7, 20140–20151 (2016).

31. Tian, Z., Yao, G., Song, H., Zhou, Y. & Geng, J. IGF2R expression is associated with the chemotherapy response and prognosis of patients with advanced NSCLC. Cell. Physiol. Biochem. 34, 1578–1588 (2014).

32. Ou, J. M. et al. Knockdown of IGF2R suppresses proliferation and induces apoptosis in hemangioma cells in vitro and in vivo. Int. J. oncol. 45, 1241–1249 (2014).

33. Livingstone, C. IGF2 and cancer. Endocr Relat Cancer 20, R321–R339 (2013).

34. Kim, S. et al. Impaired autophagy promotes bile acid-induced hepatic injury and accumulation of ubiquitinated proteins. Biochem. Biophys. Res. Commun. 495, 1541–1547 (2018).

35. Carew, J. S. et al. Autophagy inhibition enhances vorinostat-induced apoptosis via ubiquitinated protein accumulation. J. Cell Mol. Med. 14, 2448–2459 (2010).

36. Ghosh, P., Dahms, N. M. & Kornfeld, S. Mannose 6-phosphate receptors: new twists in the tale. Nat. Rev. Mol. Cell Biol. 4, 202–212 (2003).

37. Probst, O. C. et al. The 46-kDa mannose 6-phosphate receptor does not depend on endosomal acidification for delivery of hydrolases to lysosomes. J. Cell Sci. 119, 4935–4943 (2006).

38. Braulke, T. & Bonifacino, J. S. Sorting of lysosomal proteins. Biochim. Biophys. Acta 1793, 605–614 (2009).

39. Chua, M. M. et al. CK2 in Cancer: Cellular and Biochemical Mechanisms and Potential Therapeutic Target. Pharmaceuticals (Basel) 10, https://doi.org/ 10.3390/ph10010018 (2017).

40. Tugizov, S. et al. Inhibition of human papillomavirus type 16 E7 phosphor- ylation by the S100 MRP-8/14 protein complex. J. Virol. 79, 1099–1112 (2005).

41. Perera, Y. et al. Synergistic interactions of the anti-casein kinase 2 CIGB-300 peptide and chemotherapeutic agents in lung and cervical preclinical cancer models. Mol. Clin. Oncol. 2, 935–944 (2014).

42. Solares, A. M. et al. Safety and preliminary efficacy data of a novel casein kinase 2 (CK2) peptide inhibitor administered intralesionally at four dose levels in patients with cervical malignancies. BMC Cancer 9, 146 (2009).

43. Sarduy, M. R. et al. Optimizing CIGB-300 intralesional delivery in locally advanced cervical cancer. Br. J. Cancer 112, 1636–1643 (2015).

44. Lee, G. Y., Kenny, P. A., Lee, E. H. & Bissell, M. J. Three-dimensional culture models of normal and malignant breast epithelial cells. Nat. Methods 4, 359–365 (2007).

45. Negishi, A. et al. Large-scale quantitative clinical proteomics by label-free liquid chromatography and mass spectrometry. Cancer Sci. 100, 514–519 (2009).

46. Ono, M. et al. Label-free quantitative proteomics using large peptide data sets generated by nanoflow liquid chromatography and mass spectrometry. Mol Cell Proteomics 5, 1338–1347 (2006).